Trial Profile

Efficacy and safety of orelabrutinib in diffuse large B-cell lymphoma (DLBCL): a real-world analysis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Ifosfamide (Primary) ; Lenalidomide (Primary) ; Orelabrutinib (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Vincristine (Primary)
Indications Diffuse large B cell lymphoma
Focus Adverse reactions
Sponsors InnoCare Pharma

Most Recent Events

09 Jun 2022 New trial record
06 Jun 2022 Results presented in an InnoCare Pharma media release.
06 Jun 2022 According an InnoCare Pharma media release, the study results were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com